Prothena Corp. (NASDAQ: PRTA) reported Q4 EPS of ($0.40), $0.19 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $21 thousand versus the consensus estimate of $1.39 million.

2026 Financial Guidance

The Company expects its full year net cash used in operating and investing activities to be $50 to $55 million and to end the year with approximately $255 million (midpoint) in cash, cash equivalents, and restricted cash. The estimated full year 2026 net cash used from operating and investing activities is primarily driven by an estimated net loss of $67 to $72 million, which includes an estimated $24 million of non-cash share-based compensation expense. This financial guidance does not include the potential to earn up to $105 million of aggregate clinical milestone payments from strategic partners in 2026 related to the advancement of both coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerative diseases by Bristol Myers Squibb.

For earnings history and earnings-related data on Prothena Corp. (PRTA) click here.